Short-acting heparin-based anticoagulant compounds and methods

An anticoagulant activity, heparin technology, applied in chemical instruments and methods, separation methods, chemical/physical processes, etc.

Pending Publication Date: 2019-11-12
THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Synthesis of HS oligosaccharides and rel

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Short-acting heparin-based anticoagulant compounds and methods
  • Short-acting heparin-based anticoagulant compounds and methods
  • Short-acting heparin-based anticoagulant compounds and methods

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0045]Synthetic methods for the synthesis of heparin analogs are shown (see, e.g., Figure 1A , Figure 1B and Figure 8C ) and are discussed further herein, but can include, in certain aspects, providing a sugar substrate, extending the sugar substrate to a sugar of a desired or predetermined length, using a 3-O-sulfotransferase ( The 3-OST-3 isoform of the 3-OST) enzyme undergoes at least one sulfation reaction whereby a synthetic heparin analog is synthesized. The sugar substrate may comprise at least one IdoA2S-GlcNS3S disaccharide unit.

[0046] The disclosed synthetic methods for the synthesis of heparin analogs provide surprisingly high yields of heparin compounds. By way of example and not limitation, the disclosed synthetic methods for the synthesis of heparin analogs can have greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, about 20% to about 50%, about 30% to About 50%, or about 40% to about 50% yield.

[0047] Whe...

Embodiment 1

[0146] Chemoenzymatic Synthesis of Oligosaccharides Carrying GlcNS3S and GlcNS3S6S Residues

[0147] In this study, hexasaccharides (compounds 1-3, Figure 1A ) and octasaccharides (compounds 4-6, Figure 1A )Synthesis. Two 3-O-sulfotransferase (3-OST) isoforms (3-OST-1 and 3-OST-3) were used to install GlcNS3S±6S residues into different sugar sequences. The 3-OST-1 enzyme introduces sulfation to form a GlcNS3S6S residue, which is linked to a GlcA residue at the non-reducing end to form a disaccharide unit of -GlcA-GlcNS3S6S-; and the 3-OST-3 enzyme Sulfation is introduced to form a GlcNS3S residue, which is linked at the non-reducing end to an IdoA2S residue, forming a disaccharide unit of -IdoA2S-GlcNS3S-. Although 3-OST-1 has been successfully used in the synthesis of oligosaccharides in many studies 16,17,27,28 , but using 3-OST-3 to synthesize oligosaccharides comprising the -IdoA2S-GlcNS3S- disaccharide unit has not been reported yet.

[0148] Disclosed herein is th...

Embodiment 2

[0154] Structural and conformational analysis of oligosaccharides

[0155] Purity and structure analysis of compounds 1 to 6 were carried out. Figure 6E Representative data for compound 6 shown in Figure 2A and Figure 2B shown in . Compound 6 eluted as a single peak by high-resolution anion-exchange HPLC, indicating that the compound was pure ( Figure 2A ). The molecular weight of compound 6 measured by electrospray ionization mass spectrometry (ESI-MS) is 2449.43 ± 0.74, which is very close to the calculated molecular weight of 2448.92 ( Figure 2B ). The 1H-NMR spectrum of compound 6 clearly shows 8 anomeric protons, confirming that the product is an octasaccharide. The 13C-NMR and full NMR assignments of compound 6 are shown in Supplementary Figure 25 and Supplementary Table 1, respectively. To locate the 3-O-sulfo group in compound 4, tandem MS analysis was performed. In this assay, the introduction of a stable isotopically labeled [34S]sulfo group by the 3-OST...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Binding affinityaaaaaaaaaa
Login to view more

Abstract

Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.

Description

[0001] Citations to related applications [0002] This application claims the benefit of U.S. Provisional Patent Application Serial No. 62 / 469,643, filed March 10, 2017, which is incorporated herein by reference in its entirety. [0003] Authorization statement [0004] This invention was made with government support under Grant Nos. GM102137, HL094463, CA207824, and GM103390 awarded by the National Institutes of Health. The government has certain rights in this invention. technical field [0005] The subject matter disclosed herein relates generally to the synthesis of heparin compounds. More specifically, the subject matter disclosed herein relates to the chemoenzymatic synthesis of heparin compounds and synthetic heparin analogs with short acting anticoagulant activity. Background technique [0006] Heparan sulfate (HS) is a ubiquitous component of the cell surface and extracellular matrix. It regulates a wide range of physiological and pathophysiological functions, i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61M1/36B01D15/36
CPCC08B37/0075A61K31/727A61P7/02B01D15/3804Y02A50/30A61K38/4846C12P19/04C12P19/18
Inventor 刘健王章杰谢柏宏徐咏梅
Owner THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap